Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Nanobiotix ( (NBTX) ) has shared an announcement.
Nanobiotix S.A. is a late-stage clinical biotechnology group headquartered in Paris that focuses on physics-based nanotechnology platforms to improve treatment outcomes in oncology, bioavailability and biodistribution, and central nervous system disorders. Founded in 2003 and listed on both Euronext Paris and the Nasdaq Global Select Market, the company holds more than 25 patent families and maintains an international footprint with subsidiaries including Cambridge, Massachusetts, attracting a broad base of healthcare-focused investors.
On March 12, 2026, Nanobiotix reported its share capital and voting rights position as of February 28, 2026, disclosing 48,494,528 shares outstanding and 50,197,214 theoretical voting rights, of which 50,175,096 were exercisable. The disclosure, made in line with French market regulations, provides investors and regulators with up-to-date transparency on the company’s capital structure and voting power, information that can influence perceptions of shareholder concentration, threshold crossings and overall governance dynamics.
The most recent analyst rating on (NBTX) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
Spark’s Take on NBTX Stock
According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.
Nanobiotix’s overall stock score is primarily impacted by its poor financial performance, with significant operational losses and financial instability. While technical analysis shows some positive momentum, the negative valuation metrics due to lack of profitability further weigh down the score.
To see Spark’s full report on NBTX stock, click here.
More about Nanobiotix
Nanobiotix S.A. is a late-stage clinical biotechnology company headquartered in Paris that develops physics-based nanotechnology platforms aimed at improving treatment outcomes, primarily in oncology as well as in bioavailability, biodistribution and central nervous system disorders. Founded in 2003 and listed on Euronext Paris and the Nasdaq Global Select Market, the company holds more than 25 patent families and operates through subsidiaries including a presence in Cambridge, Massachusetts, targeting a global healthcare and biopharma investor base.
The company’s work centers on three nanotechnology platforms designed to enhance cancer therapies and other complex indications, positioning Nanobiotix as an innovation-driven player in advanced therapeutic technologies. Its dual listing in Europe and the U.S. broadens access to capital markets and international investors, supporting its late-stage clinical development programs and long-term commercialization ambitions.
Average Trading Volume: 36,221
Technical Sentiment Signal: Buy
Current Market Cap: $1.62B
Learn more about NBTX stock on TipRanks’ Stock Analysis page.